PTGX Protagonist Therapeutics, Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1377121 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY163.7%
TTM net income YoY645.5%
TTM EPS YoY616.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin58.6%
Net margin62.0%
FCF margin19.8%
EBITDA margin58.9%
Returns
ROE39.6%
ROA37.0%
ROIC (approx.)56.5%
Asset turnover0.60x
Leverage & solvency
Liabilities / assets5.4%
Debt / equity0.00x
Current ratio19.85x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio25.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M |
| R&D expense | $159.29M | $138.13M | $120.16M | $126.22M | $126.01M |
| SG&A expense | $44.85M | $43.46M | $33.49M | $31.74M | $27.20M |
| Operating income | -$158.13M | $252.84M | -$93.65M | -$131.37M | -$125.84M |
| Pretax income | -$129.31M | $279.41M | -$78.95M | -$127.39M | -$125.55M |
| Income tax | $838,000 | $4.22M | $0 | $0 | $0 |
| Net income | -$130.15M | $275.19M | -$78.95M | -$127.39M | -$125.55M |
| EBITDA | -$156.85M | $253.67M | -$92.67M | -$130.34M | -$125.03M |
| EPS (basic) | -2.05 | 4.47 | -1.39 | -2.60 | -2.71 |
| EPS (diluted) | -2.05 | 4.23 | -1.39 | -2.60 | -2.71 |
| Weighted avg. shares (diluted) | 63.57M | 65.08M | 56.76M | 49.04M | 46.32M |
| Balance sheet | |||||
| Cash & equivalents | $128.39M | $97.47M | $186.73M | $125.97M | $123.89M |
| Short-term investments | $438.97M | $321.66M | $154.89M | $111.61M | $203.24M |
| Current assets | $577.57M | $591.64M | $355.58M | $243.08M | $340.74M |
| PP&E, net | $3.86M | $3.19M | $1.20M | $1.56M | $1.80M |
| Total assets | $668.19M | $744.73M | $357.95M | $247.93M | $347.69M |
| Current liabilities | $45.44M | $47.40M | $21.27M | $31.18M | $44.02M |
| Total liabilities | $53.48M | $69.43M | $21.27M | $32.32M | $47.67M |
| Shareholders' equity | $614.71M | $675.29M | $336.68M | $215.61M | $300.02M |
| Shares outstanding | 62.58M | 61.04M | 57.71M | 49.34M | 47.84M |
| Cash flow statement | |||||
| Operating cash flow | $57.67M | $184.15M | -$70.24M | -$108.14M | -$107.86M |
| Capital expenditure | $1.59M | $1.35M | $609,000 | $795,000 | $1.10M |
| Free cash flow | $56.08M | $182.80M | -$70.84M | -$108.93M | -$108.97M |
| Investing cash flow | -$49.33M | -$299.48M | -$39.26M | $91.47M | -$15.86M |
| Financing cash flow | $22.86M | $25.85M | $170.48M | $18.84M | $129.92M |
| Depreciation & amortization | $1.28M | $826,000 | $977,000 | $1.03M | $813,000 |
| Stock-based compensation | $45.97M | $37.55M | $29.29M | $24.20M | $16.39M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.